SCHEMBL378252

SCHEMBL378252

COc1cc(OC)c2c(=O)[nH]c(-c3ccc(N4CCCN(C)CC4)cc3)nc2c1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.61
ALDH1A1 P00352 4/20 0.61
MAPT P10636 3/20 0.61
BRD4 O60885 7/20 0.57
BRD2 P25440 1/20 0.57
CSNK1A1 P48729 1/20 0.57
CSNK1D P48730 1/20 0.57
CSNK1E P49674 1/20 0.57
CSNK1G2 P78368 1/20 0.57
BRD3 Q15059 1/20 0.57
CSNK1G1 Q9HCP0 1/20 0.57
IL17A Q16552 1/20 0.54
TNKS O95271 1/20 0.52
PARP1 P09874 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
POLB P06746 2/20 0.51
HPGD P15428 1/20 0.51
HDAC3 O15379 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348420 0.96 KDM4E (0.65) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL30053201 0.96 KDM4E (0.65) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL30458677 0.88 BRD4 (0.56) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL378514 0.87 BRD4 (0.56) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL377771 0.86 BRD4 (0.55) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL30053496 0.86 BRD4 (0.58) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL378020 0.86 BRD4 (0.58) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL348652 0.86 BRD4 (0.58) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL30052318 0.85 BRD4 (0.55) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL377720 0.85 BRD4 (0.55) KDM4EALDH1A1MAPTBRD4BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP claimed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 US claimed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US claimed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US claimed
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 KDM4E 3982/4885ALDH1A1 587/4885MAPT 2112/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KDM4E 3726/4885ALDH1A1 650/4885MAPT 2027/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 KDM4E 342/4885ALDH1A1 3920/4885MAPT 1238/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 KDM4E 3982/4885ALDH1A1 587/4885MAPT 2112/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KDM4E 3982/4885ALDH1A1 587/4885MAPT 2112/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 KDM4E 3982/4885ALDH1A1 587/4885MAPT 2112/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KDM4E 3726/4885ALDH1A1 650/4885MAPT 2027/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KDM4E 3726/4885ALDH1A1 650/4885MAPT 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.